No treatment or drug gets to market without a clinical trial. Many of those trials don’t just happen in academic settings, ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

Q4 2024 Management View CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

Data from the Phase II multi-center randomized controlled trial evaluating treatment of Wagner I Diabetic Foot Ulcers with SkinTE® plus standard of care (SOC) vs SOC alone ( NCT03881254) that ...

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...